Studying the effect of letrozole in embryo transfer cycles in patients with adenomyosis

Investigating the effect of simultaneous administration of letrozole and GnRH agonist compared to agonist alone in embryo transfer cycles in adenomyosis patients on pregnancy rates and pregnancy outcomes.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20241214064048N1

Enrollment

Registered

2025-01-21

Start date

2025-04-03

Completion date

Unknown

Last updated

2025-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pregnancy Outcomes. Outcome of delivery

Interventions

Intervention 1: In the first group, the Long HRT protocol is two months of GnRH agonist Diffrelin 3.75 as a monthly injection, 14 days after the second injection, in case of thin endometrial thickness

Eligibility

Sex/Gender

Female

Age

18 Years to 40 Years

Inclusion criteria

Inclusion criteria: Infertile women with menstrual cycles of 21 to 35 days Women under 40 years of age at the time of oocyte retrieval and embryo transfer Diagnosis of adenomyosis based on clinical symptoms and ultrasound Consent to participate in the study

Exclusion criteria

Exclusion criteria: Having uterine malformations Having endometrial polyps Having leiomyoma PCOS according to the Rotterdam criteria Having acute and chronic systemic diseases Unwillingness to participate in the study

Design outcomes

Primary

Measure	Time frame
Pregnancy rate. Timepoint: 14 day. Method of measurement: Clinical examination.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactTiba Mirzarahimi

Ardabil University of Medical Sciences

alavi@arums.ac.ir+98 45 3324 8888

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026